Alka-372–001: first-in-human, phase I study of entrectinib – an oral pan-trk, ROS1, and ALK inhibitor – in patients with advanced solid tumors with relevant molecular alterations - De Braud, F G; Niger, M; Damian, S (J Clin Oncol, 2015)
(Suppl): abstract 2517